Berlin Braces for US Pressure as Drug Pricing Dispute Puts Tariffs on the Table

United States officials are travelling to Berlin for talks focused on German pharmaceutical pricing, with Berlin working to avert threatened American tariffs linked directly to how the country values new medicines.

The friction stems from the mechanics of medicine pricing in Europe’s largest economy. Washington has objected to the prices Germany sets for novel drugs, raising the prospect of punitive customs duties if the system is not adjusted. In response, German authorities are entering direct discussions to defuse transatlantic tensions before the tariff threat turns into concrete economic retaliation. Beyond the core objective of heading off duties, specific terms and negotiating texts have not been made public.

For ordinary patients and taxpayers, the way a country prices new treatments is rarely thought of as a matter of international trade diplomacy. European healthcare systems rely on stringent national assessments to decide what public insurance funds will pay for innovative drugs, aiming to balance patient access with statutory budget limits.

When a major trading partner ties tariff threats to those domestic pricing decisions, the dispute ceases to be a purely bureaucratic discussion about healthcare reimbursements. An escalation risks penalising broader economic sectors with customs duties simply because a government negotiated tough discounts on medicine, establishing an uncomfortable precedent for how domestic health spending is challenged abroad.

In the EU capital, bilateral talks between Washington and an individual member state under the shadow of trade retaliation trigger familiar procedural unease. Trade policy is an exclusive competence of the European Commission, meaning no individual capital has the legal mandate to negotiate commercial side-deals or tariff carve-outs on its own.

Yet healthcare organisation and drug pricing remain strictly member-state competences, jealously guarded by national capitals against any EU interference. That constitutional split leaves Germany in a delicate institutional corner: it must discuss its domestic medicine pricing without formally negotiating on trade, an area where only Brussels holds the pen. While EU officials are not running the Berlin room, they will watch closely to ensure member-state diplomacy does not compromise the bloc’s single commercial front.

Delegations in Berlin will sit down to explore whether Germany can offer sufficient reassurances on pharmaceutical market terms to convince Washington to drop its tariff warnings. No timetable for a resolution has been announced, and should the talks falter, the dispute could eventually force the European Commission to step in and defend common EU trade policy against external tariff pressure.